M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Pharmaceutical Business ReviewThe value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.Rare DiseaseRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaceutical Business Review The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO26: AZ triplet makes waves in frontline liver cancerNext: ASCO26: Symptom-tracking app helps advanced cancer patients Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
